Celgene’s Revlimid wins additional FDA lymphoma approval

(Reuters) – Celgene Corp said on Wednesday that its flagship blood cancer drug, Revlimid, was approved by U.S. health regulators to treat mantle cell lymphoma, adding another revenue source for the $4 billion-a-year medicine. The U.S. Food and Drug Administration approved Revlimid to treat mantle cell lymphoma (MCL) – a type of non-Hodgkin’s lymphoma – that has relapsed or progressed following two prior treatment regimens, one of which must include Takeda Pharmaceutical Co’s Velcade. …